← All trials
NCT02419664
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2015
- Primary completion
- Jan 13, 2022
- Completion date
- Jan 13, 2022
- First posted
- Apr 17, 2015
- Last posted
- Mar 31, 2022
- Enrollment
- 22
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GothenburgLead sponsor
- University of GothenburgCollaborator
- Uppsala UniversityCollaborator
- University of GothenburgOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.